NCT01153893

Immunization of Children Previously Primed With GSK Pneumococcal Vaccine GSK1024850A and of Unprimed Children in Nigeria

Safety, Reactogenicity and Immunogenicity Study of GSK Biologicals' Pneumococcal Vaccine GSK1024850A, Given Either as a Booster Dose or as a 2-dose Catch-up Immunization in Healthy Nigerian Children

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 105 (actual)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 15 Months – 21 Months
• Healthy volunteers: Accepted

Summary

The purpose of this trial is to assess the safety, reactogenicity and immunogenicity of GSK Biologicals' pneumococcal conjugate vaccine GSK1024850A when administered either as a booster dose or as a two dose catch-up vaccination in the second year of life to the Nigerian subjects previously enrolled in the primary vaccination study NCT00678301. This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00678301).

Conditions

• Infections, Streptococcal

Interventions

Type	Name	Description
BIOLOGICAL	Pneumococcal vaccine GSK1024850A	Intramuscular injection, 1 or 2 doses
BIOLOGICAL	InfanrixTM	Intramuscular injection, 1dose

Timeline

• Start date: 2010-10-04
• Primary completion: 2011-02-16
• Completion: 2011-02-16
• First posted: 2010-06-30
• Last updated: 2018-09-20
• Results posted: 2012-03-15

Locations

1 site across 1 country: Nigeria